摘要
[目的]观察125I粒子植入联合化疗治疗复发鼻咽癌的临床疗效。[方法]对60例患者分别行125I粒子植入联合化疗和单纯化疗,观察其治疗前后复发病灶和EB病毒抗体滴度、血沉(ESR)、不良反应变化情况。[结果]125I粒子植入联合化疗后的复发病灶CR 15例,PR 12例,SD 3例;对照组复发病灶CR 3例,PR 9例,SD 15例,PD 3例。125I粒子植入联合化疗组EB病毒抗体滴度下降27例,稳定3例;对照组下降12例,稳定15例,上升3例。125I粒子植入联合化疗组治疗前后ESR比较有显著性差异(P=0.029)。两组患者治疗前后不良反应无显著性差异。[结论]125I粒子植入联合化疗对复发鼻咽癌的局部控制率高,不良反应小,值得临床进一步推广。
[Purpose] To evaluate the clinical efficacy of permanent implantation of radioactive iodine 125 combined with chemotherapy in the recurrent nasopharyneal cancer patients.[Methods] Sixty cases accepted the permanent implantation of iodine 125 combined with chemotherapeu- tics or only chemotherapeutics respectively. [Results] Recrudescent focus had 15 cases,CR; 12 cases,PR;3 cases,SD of the group of permanent implantation of iodine 125 seeds combined with chemotherapy group and the control group had 3 cases,CR;9 cases,PR;15 cases,SD;3 cases,PD. There was 27 cases descend,3 cases stabilization of EB virus antibody titer in the group of permanent implantation of iodine 125 seeds associated with ehemotherapeutics, 12 cases descend, 15 cases stabilization,3 cases ascend in the control group. The ESR cross-refer- ence of the group of permanent implantation of iodine 125 seeds combined with chemothera- peutics was prominent（P=0.029）,and the descender range（2.84±0.67） was prominent（P=0.0009） compared with control group （1.46±0.63）. Adverse events cross-reference of two groups was not prominent. [Conclusion] There are high control rate and slight adverse events for recurrent na- sopharyneal cancer patients treated with the implantation of iodine 125 combined with chemotherapy. It is worthy of popularization in clinic.
出处
《肿瘤学杂志》
CAS
2013年第8期636-638,共3页
Journal of Chinese Oncology
基金
广东省中医药局建设中医药强省科研项目(2010257)
